The combination of isosorbide dinitrate and hydralazine is specifically indicated to reduce mortality in which specific population with heart failure?
- A Black patients with reduced ejection fraction ✓
- B Asian patients with preserved ejection fraction
- C Patients with right heart failure
- D Patients with hypertrophic cardiomyopathy
Correct answer: A. Black patients with reduced ejection fraction
Explanation
The B-HeFT trial demonstrated that the fixed-dose combination of isosorbide dinitrate and hydralazine significantly reduces mortality and hospitalization when added to standard therapy in Black patients with heart failure with reduced ejection fraction. This is a specific guideline-directed therapy for this demographic.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.